Emcure Pharmaceuticals (EMCURE) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 18% year-over-year to ₹1,963 crore, with adjusted PAT up 36% and reported PAT at ₹156 crore, up 30.3% YoY.

• Domestic business grew 12% YoY to ₹888 crore, while international business rose 23% YoY to ₹1,075 crore, led by strong performance in Canada (up 34%) and emerging markets (up 40%).

• Strategic focus areas include derma (Emcutix subsidiary), ophthalmology (Bevacizumab), and expansion in women's health, oncology, and biosimilars.

• Integration of Sanofi's cardiodiabetes portfolio and Mantra acquisition are underway, driving growth and margin improvement.

• EBITDA for the quarter was ₹362 crore, up 23% YoY, with margins at 18.4%.

Financial highlights

• Q3 revenue: ₹1,963 crore (+18% YoY); domestic: ₹888 crore (+12% YoY); international: ₹1,075 crore (+23% YoY).

• Canada sales grew 34% to ₹352 crore; emerging markets up 40% to ₹365 crore; Europe up 2% to ₹358 crore.

• Gross margin for Q3 was 60.1% (vs. 62.7% YoY); EBITDA (ex-other income) grew 23% YoY to ₹362 crore; EBITDA margin at 18.4%.

• Adjusted PAT before one-time tax: ₹171 crore (+43% YoY); reported PAT: ₹156 crore (up 30.3% YoY).

• Net debt at quarter end: ₹600 crore, down from ₹705 crore in Q2; working capital days stable at 96.

Outlook and guidance

• FY25 revenue growth expected at 18-19% (vs. 20% guided earlier); margins to end at 18.5-19% (ex-other income).

• Margin improvement of 300-400 bps targeted over 3-4 years, driven by operating leverage, new launches, and productivity gains.

• Domestic growth to accelerate with new launches in derma, ophthalmology, and oncology; international growth led by differentiated products.

• Europe growth to pick up to high single digits in FY26 as new approvals come through.

• Focus on leveraging in-licensed portfolios and driving synergies from Sanofi cardiovascular products.